{"id":"colesevelam-hcl","safety":{"commonSideEffects":[{"rate":"11-12","effect":"Constipation"},{"rate":"8-10","effect":"Dyspepsia"},{"rate":"5-8","effect":"Nausea"},{"rate":"5-7","effect":"Abdominal pain"},{"rate":"4-6","effect":"Flatulence"}]},"_chembl":{"chemblId":"CHEMBL1201473","moleculeType":"Unknown"},"_dailymed":{"setId":"5eb26657-09cf-4229-a567-1395b58bba6b","title":"COLESEVELAM HCL TABLET, FILM COATED [A-S MEDICATION SOLUTIONS]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By binding bile acids in the gastrointestinal tract, colesevelam prevents their enterohepatic circulation and increases their elimination in feces. This stimulates the liver to convert more cholesterol into bile acids to replace those lost, thereby reducing serum LDL cholesterol levels. The drug may also improve glycemic control through effects on glucose metabolism and GLP-1 signaling.","oneSentence":"Colesevelam is a bile acid sequestrant that binds bile acids in the intestine, preventing their reabsorption and increasing their fecal excretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:21:59.382Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia (elevated LDL cholesterol)"},{"name":"Type 2 diabetes mellitus (as adjunctive therapy for glycemic control)"}]},"trialDetails":[{"nctId":"NCT07226440","phase":"PHASE1, PHASE2","title":"Examining a Novel Gastrointestinal Intervention to Negate Environmental Toxicants (ENGINE)","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-03-01","conditions":"Toxicant Exposure, Firefighter, Occupational Exposure to Chemicals","enrollment":40},{"nctId":"NCT03767257","phase":"PHASE2","title":"A Study of Colesevelam for Lenalidomide-Associated Diarrhea","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-12-03","conditions":"Multiple Myeloma, Diarrhea","enrollment":25},{"nctId":"NCT03110432","phase":"","title":"Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry","status":"COMPLETED","sponsor":"GWT-TUD GmbH","startDate":"2017-05-18","conditions":"Dyslipoproteinemias, Hypercholesterolemia, Familial, Familial Hypercholesterolemia - Homozygous","enrollment":1695},{"nctId":"NCT06925997","phase":"EARLY_PHASE1","title":"Metabolic Effects of Endogenous Bile Acids After Gastric Bypass Surgery","status":"RECRUITING","sponsor":"Hvidovre University Hospital","startDate":"2024-05-02","conditions":"Bariatric Surgery Candidate, Bile Acid, Elevated Serum, Glucose Metabolism Disorders","enrollment":18},{"nctId":"NCT05252988","phase":"PHASE2","title":"Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Breast Cancer Research Group","startDate":"2022-08-31","conditions":"Early-stage Breast Cancer, HER2 Positive Breast Cancer, Hormone Receptor Positive","enrollment":177},{"nctId":"NCT06197763","phase":"PHASE1, PHASE2","title":"Impact of Therapy Using Colesevelam Treatment Reducing Bile Acids in Patients With Fontan Circulation.","status":"NOT_YET_RECRUITING","sponsor":"St. Boniface Hospital","startDate":"2024-06-01","conditions":"Fontan Circulation","enrollment":50},{"nctId":"NCT02628626","phase":"PHASE3","title":"A Study of Colesevelam in Fecal Incontinence","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2015-11","conditions":"Fecal Incontinence, Bile Acid Malabsorption","enrollment":88},{"nctId":"NCT03876717","phase":"PHASE4","title":"Effect of the Sequestrant Colesevelam in Bile Acid Diarrhoea","status":"COMPLETED","sponsor":"Lars Kristian Munck","startDate":"2018-10-25","conditions":"Bile Acid Malabsorption, Chronic Diarrhea","enrollment":255},{"nctId":"NCT00715273","phase":"PHASE4","title":"Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication","status":"COMPLETED","sponsor":"University of Washington","startDate":"2001-05-01","conditions":"Coronary Artery Disease, Carotid Artery Diseases, Atherosclerosis","enrollment":217},{"nctId":"NCT03955575","phase":"PHASE4","title":"Treatment of Bile Acid Malabsorption With Liraglutide","status":"COMPLETED","sponsor":"Filip Krag Knop","startDate":"2019-03-07","conditions":"Bile Acid Malabsorption","enrollment":52},{"nctId":"NCT04003181","phase":"NA","title":"The Pathogenesis of Chronic Diarrhoea After Treatment for Cancer in Cecum and the Ascending Colon","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2017-09-28","conditions":"Colon Adenocarcinoma, Diarrhea","enrollment":64},{"nctId":"NCT01258075","phase":"PHASE4","title":"Colesevelam for Children With Type 2 Diabetes","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2011-02-24","conditions":"Type 2 Diabetes Mellitus","enrollment":236},{"nctId":"NCT02876484","phase":"PHASE4","title":"Effects of Bile Acids and Bile Acid Sequestrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass","status":"COMPLETED","sponsor":"Hvidovre University Hospital","startDate":"2016-06","conditions":"Severe Obesity","enrollment":12},{"nctId":"NCT02952963","phase":"PHASE4","title":"Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass","status":"COMPLETED","sponsor":"Hvidovre University Hospital","startDate":"2016-10","conditions":"Severe Obesity","enrollment":8},{"nctId":"NCT01948648","phase":"NA","title":"Effects of Fish Oil and Colesevelam (STAIR7007)","status":"UNKNOWN","sponsor":"University of Manitoba","startDate":"2018-02-06","conditions":"Sitosterolemia","enrollment":13},{"nctId":"NCT01066364","phase":"PHASE2","title":"Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2010-02","conditions":"Nonalcoholic Steatohepatitis","enrollment":59},{"nctId":"NCT03270085","phase":"PHASE2","title":"Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-12-07","conditions":"Chronic Diarrhea, Irritable Bowel Syndrome With Diarrhea, Bile Acid Malabsorption","enrollment":30},{"nctId":"NCT02504736","phase":"","title":"Colesevelam, Lipids And Sugars, South Asian Canadian Trial","status":"COMPLETED","sponsor":"Canadian Collaborative Research Network","startDate":"2015-06","conditions":"Dyslipidemia","enrollment":90},{"nctId":"NCT02682680","phase":"PHASE4","title":"Randomized Trial Comparing Colesevelam vs. Ezetimibe","status":"COMPLETED","sponsor":"LMC Diabetes & Endocrinology Ltd.","startDate":"2016-01-11","conditions":"Type 2 Diabetes Mellitus","enrollment":200},{"nctId":"NCT03009916","phase":"PHASE4","title":"Bileacid Malabsorption and GLP-1 Secretion","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2016-03","conditions":"Bileacid Malabsorption","enrollment":24},{"nctId":"NCT00789750","phase":"PHASE3","title":"Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2009-04","conditions":"Type 2 Diabetes Mellitus","enrollment":562},{"nctId":"NCT02619812","phase":"PHASE2","title":"Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2016-04","conditions":"Multiple Myeloma","enrollment":4},{"nctId":"NCT00249938","phase":"PHASE4","title":"Evaluation of Combination Cholesterol Treatments in Patients With High Cholesterol.","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2005-03","conditions":"Hyperlipidemia, Dyslipidemia","enrollment":60},{"nctId":"NCT00484419","phase":"PHASE3","title":"Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2007-05","conditions":"Type 2 Diabetes, Hyperlipidemia","enrollment":169},{"nctId":"NCT02111603","phase":"PHASE4","title":"Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2014-04","conditions":"Diarrhea Predominant Irritable Bowel Syndrome","enrollment":13},{"nctId":"NCT00993824","phase":"PHASE2, PHASE3","title":"Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2009-09","conditions":"Type 2 Diabetes","enrollment":21},{"nctId":"NCT01656057","phase":"NA","title":"The Impact of Gall Bladder Emptying and Bile Acids on the Human GLP-1-secretion","status":"COMPLETED","sponsor":"Filip Krag Knop","startDate":"2012-07","conditions":"To Assess the Impact of Bile Acids on Human Glukagon-like-peptide-1 Secretion","enrollment":10},{"nctId":"NCT00692250","phase":"PHASE1","title":"A Study to Assess Any Potential Interaction Between Colesevelam and Ciclosporin in Healthy Volunteers","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2007-09","conditions":"Healthy","enrollment":14},{"nctId":"NCT00753779","phase":"PHASE4","title":"A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Simvastatin for at Least 4 Weeks.","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2002-11","conditions":"Hypercholesterolemia","enrollment":72},{"nctId":"NCT00754039","phase":"PHASE4","title":"Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2003-02","conditions":"Hypercholesterolemia, Hyperlipidemia, Familial Combined","enrollment":129},{"nctId":"NCT00755352","phase":"PHASE4","title":"A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Pravastatin for at Least 4 Weeks.","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2002-11","conditions":"Hypercholesterolemia","enrollment":67},{"nctId":"NCT00754507","phase":"PHASE4","title":"A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Atorvastatin for at Least 4 Weeks.","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2002-11","conditions":"Hypercholesterolemia","enrollment":65},{"nctId":"NCT00476710","phase":"","title":"Effects of Colesevelam HCl On Bile Acid Kinetics","status":"COMPLETED","sponsor":"KineMed","startDate":"2007-05","conditions":"Type 2 Diabetes Mellitus, Impaired Glucose Tolerance","enrollment":36},{"nctId":"NCT02050074","phase":"PHASE4","title":"The Role of Metformin and Colesevelam in Human GLP-1 Secretion","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2014-01","conditions":"Type 2 Diabetes","enrollment":12},{"nctId":"NCT00938405","phase":"NA","title":"Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2009-07","conditions":"Diabetes Mellitus, Type 1, Hyperlipidemias","enrollment":45},{"nctId":"NCT00147745","phase":"PHASE2","title":"Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2005-06","conditions":"Type 2 Diabetes","enrollment":36},{"nctId":"NCT00690937","phase":"PHASE2","title":"A Multicenter, Active and Placebo-controlled Study of Enteric Coated Sevelamer in Patients With Mild to Moderate Hypercholesteremia","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2008-02","conditions":"Hypercholesterolemia","enrollment":120},{"nctId":"NCT00789737","phase":"PHASE3","title":"Welchol as Monotherapy for Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2009-01","conditions":"Type 2 Diabetes Mellitus","enrollment":357},{"nctId":"NCT00655265","phase":"PHASE4","title":"A Study of the Safety and Efficacy of Patients With Familial Hypercholesterolaemia Taking Colesevelam as add-on Therapy to Their Existing Medication","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2007-08","conditions":"Familial Hypercholesterolemia","enrollment":86},{"nctId":"NCT01666223","phase":"NA","title":"Effect of Bile Acids on GLP-1 Secretion","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2012-11","conditions":"Type 2 Diabetes, Obesity","enrollment":20},{"nctId":"NCT00951899","phase":"PHASE4","title":"The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2009-08","conditions":"Type 2 Diabetes","enrollment":38},{"nctId":"NCT01203254","phase":"PHASE4","title":"Colesevelam for the Treatment of Bile Acid Malabsorption in Patients With Crohn's Disease","status":"TERMINATED","sponsor":"Florian Beigel","startDate":"2010-10","conditions":"Crohns Disease, Bile Acid Malabsorption","enrollment":34},{"nctId":"NCT01092663","phase":"NA","title":"The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"KineMed","startDate":"2010-03","conditions":"Diabetes Mellitus, Type 2","enrollment":61},{"nctId":"NCT00756171","phase":"PHASE2, PHASE3","title":"Colesevelam Versus Placebo in Cholestatic Pruritus","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2008-09","conditions":"Chronic Liver Disease","enrollment":38},{"nctId":"NCT00990184","phase":"PHASE3","title":"Study to Evaluate the Effects of Colesevelam on Insulin Sensitivity and ß-Cell Function in Subjects With Impaired Fasting Glucose (Prediabetes)","status":"COMPLETED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2009-09","conditions":"Impaired Fasting Glucose, Prediabetes","enrollment":21},{"nctId":"NCT00596427","phase":"NA","title":"Mechanisms of Glucose Lowering Effect of Colesevelam HCl","status":"COMPLETED","sponsor":"Carine Beysen","startDate":"2007-11","conditions":"Diabetes","enrollment":60},{"nctId":"NCT00911612","phase":"PHASE2","title":"Does Welchol (Colesevelam Hydrochloride) Improve Colonic Transit in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)?","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2009-01","conditions":"Irritable Bowel Syndrome, Diarrhea","enrollment":24},{"nctId":"NCT00151749","phase":"PHASE3","title":"WelChol® and Insulin in Treating Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2004-06","conditions":"Type 2 Diabetes","enrollment":260},{"nctId":"NCT00147758","phase":"PHASE3","title":"WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2004-06","conditions":"Type 2 Diabetes","enrollment":400},{"nctId":"NCT00147719","phase":"PHASE3","title":"WelChol® With Metformin in Treating Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2004-06","conditions":"Type 2 Diabetes","enrollment":300},{"nctId":"NCT01239004","phase":"PHASE4","title":"Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy","status":"COMPLETED","sponsor":"Radiant Research","startDate":"2010-11","conditions":"Dyslipidemia, Hyperlipidemia, Hyperglycemia","enrollment":140},{"nctId":"NCT01122108","phase":"PHASE4","title":"Comparison of Colesevelam Hydrogen Chloride (HCl) Powder For Oral Suspension Versus Generic Cholestyramine Through Use of the Bile Acid Sequestrant Acceptability (BASA) Scale","status":"COMPLETED","sponsor":"Louisville Metabolic and Atherosclerosis Research Center","startDate":"2010-04","conditions":"Healthy","enrollment":42},{"nctId":"NCT00570739","phase":"PHASE3","title":"Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2007-11","conditions":"Type 2 Diabetes Mellitus, Hypercholesterolemia, Pre-diabetes","enrollment":502},{"nctId":"NCT00145574","phase":"PHASE4","title":"Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2005-11","conditions":"Hypercholesterolemia","enrollment":194},{"nctId":"NCT00361153","phase":"PHASE2","title":"Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2006-05","conditions":"Type 2 Diabetes Mellitus","enrollment":35},{"nctId":"NCT00151762","phase":"PHASE3","title":"Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2004-12","conditions":"Type 2 Diabetes","enrollment":780},{"nctId":"NCT00185107","phase":"PHASE4","title":"Effect of Combination Therapy With Two Drugs (Colesevelam and Ezetimibe) in Patients With High Cholesterol","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2005-03","conditions":"Hypercholesterolemia","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[{"date":"20231004","type":"SUPPL","sponsor":"ALKEM LABS LTD","applicationNumber":"ANDA209038"},{"date":"20231004","type":"SUPPL","sponsor":"ALKEM LABS LTD","applicationNumber":"ANDA209038"},{"date":"20231004","type":"SUPPL","sponsor":"ALKEM LABS LTD","applicationNumber":"ANDA209038"},{"date":"20181005","type":"ORIG","sponsor":"ALKEM LABS LTD","applicationNumber":"ANDA209038"}],"publicationCount":60,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Welchol","WELCHOL (colesevelam hydrochloride)","Initial U.S. Approval: 2000","WelChol"],"phase":"marketed","status":"active","brandName":"colesevelam HCl","genericName":"colesevelam HCl","companyName":"HealthPartners Institute","companyId":"healthpartners-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Colesevelam is a bile acid sequestrant that binds bile acids in the intestine, preventing their reabsorption and increasing their fecal excretion. Used for Hypercholesterolemia (elevated LDL cholesterol), Type 2 diabetes mellitus (as adjunctive therapy for glycemic control).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}